Stock Quote
Gilead Sciences, Inc. (GILD.O) (Nasdaq)
$47.01
23 Nov 2009
+1.34%
$47.01
--
4,848,149
$47.13
$46.54
$53.28
$40.62
0.50
6,147,778
GILD.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Martin, John | Chairman of the Board, Chief Executive Officer | 10,998,000 |
| Milligan, John | President, Chief Operating Officer | 5,187,440 |
| Washington, Robin | Chief Financial Officer, Senior Vice President | 1,166,870 |
Profile
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France,... Full Description
Company Address
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City CA 94404
P: +1650.5743000
F: +1650.5789264
333 Lakeside Drive
Foster City CA 94404
P: +1650.5743000
F: +1650.5789264
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| GlaxoSmithKline plc | £1,272.50 | -5.00 |
| Abbott Laboratories | $53.13 | -0.51 |
| Merck & Co., Inc. | $36.42 | -0.04 |
| GILD.O | Industry | |
|---|---|---|
| P/E(TTM) | 18.36 | 12.80 |
| P/S(TTM) | 6.60 | 29.90 |
| ROI(TTM) | 38.22 | 2.35 |
| ROE(TTM) | 48.95 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.80 |
| EPS Est. (Current Year) | 2.81 |
| Total Revenue | $1,801.39M |
| Net Income | $670.48M |
| EPS | $0.72 |
